Close

Anti-CD123 (32716) h(CD28-41BB-CD3ζ) CAR, pCDCAR1 (CAR-YF406)

Online Inquiry  Datasheet

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

The vector of anti-CD123 chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target human CD123. The T cells are genetically modified through transduction with a lentiviral vector expressing scFv of anti-CD123 antibody linked to CD28-41BB and CD3ζ signaling domains. And the vector product was designed for the treatment of AML.

Specific Inquiry

  • Size:
  • Marker:
  • Form:
  Add to Cart

Details

  • Target
  • CD123
  • Targeting Cell Type
  • T Cell
  • Targeting Diseases
  • AML
  • Generation
  • Third
  • Vector Name
  • pCDCAR1
  • Vector Length
  • ~8kb
  • Vector Type
  • Lentiviral vector
  • Receptor Construction
  • scFv-CD28-41BB-CD3ζ
  • Discription of Signaling Cassetes
  • CD28
    CD28 (Cluster of Differentiation 28) is one of the proteins expressed on T cells that provide co-stimulatory signals required for T cell activation and survival. CD28 is the receptor for CD80 (B7.1) and CD86 (B7.2) proteins which are expressed on antigen-presenting cells (APC). CD28 modulates the primary TCR/CD3ζ signal in a different fashion than the late costimulatory elements OX40 and 4-1BB. CD28 enhances the expression of downstream regulators that impact on T-cell proliferation, death, differentiation, and effector functions. CAR T cell containing the CD28 endodomain showed strikingly enhanced sustained T cell activation, growth, survival. And CD28 results in a brightly expressed, stable receptor as the transmembrane domain. Including CD28 costimulatory domains in CARs led to enhanced anti-malignancy efficacy.

    41BB
    CD137 (also known as 4-1BB) is a surface co-stimulatory glycoprotein originally described as present on activated T lymphocytes, which belongs to the tumor necrosis factor (TNF) receptor superfamily. It is expressed mainly on activated CD4+ and CD8+ T cells, and binds to a high-affinity ligand (4-1BBL) expressed on several antigen-presenting cells such as macrophages and activated B cells. On the basis of preclinical observation, this molecule can promote the persistence of antigen-specific and antigen-nonspecific chimeric antigen receptor T-cells to significantly increases antitumor activity.

    CD3ζ
    CD3ζ, also known as T-cell receptor zeta, which together with T-cell receptor and CD3γ, δ , ε chain, forms the TCR-CD3 complex. ζ was expressed independently from the complex. The zeta chain plays an important role in coupling antigen recognition to several intracellular signal-transduction pathways. CD3-zeta, which contains 3 ITAMs, is the most commonly used endodomain component of CARs. It transmits an activation signal to the T cell after antigen is bound. CD3-zeta may not provide a fully competent activation signal and additional co-stimulatory signaling is needed. For example, chimeric CD28 and OX40 can be used with CD4-zeta to transmit a proliferative/survival signal, or all three can be used together.

Target

  • Clone
  • 32716
  • Host
  • Mouse
  • Target Species
  • Human
  • Gene Name
  • prominin 1
  • Synonyms
  • PROM1, prominin 1

Customize Your CAR Products

Cannot find the desired product? Don't worry, just try our online CAR and CAR cell customizing system, which offers full options to meet all unique needs, including but not limited to conventional or unconventional CAR constructs, as well as a variety of vectors and cells. The customization process can be completed with just a few simple clicks, please feel free to try it out.
CAR and CAR Cell Customizing System
  • Published Data
Complete CAR data FCM

Fig.1 CD123-specific CARs can be expressed in healthy donor human T cells.

CAR Construction : 32716 scFv-28ζ Latest CAR Construction

Fig.1 CD123-specific CARs can be expressed in healthy donor human T cells.

Representative phenotype of mock- and lenti-transduced T cells derived from a single healthy donor. After immunomagnetic selection and 1 cycle of expansion, CAR-modified T cells were stained with biotinylated anti-Fc or biotinylated anti-cetuximab followed by phycoerythrin-conjugated streptavidin and anti-TCRα/β, anti-CD4, or anti-CD8 and analyzed by flow cytometry. Quadrant placement is based on staining with isotype controls, and the percentage of cells falling in each quadrant is indicated.

Mardiros, A., Dos Santos, C., McDonald, T., Brown, C. E., Wang, X., Budde, L. E., ... & Forman, S. J. (2013). T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia. Blood, The Journal of the American Society of Hematology, 122(18), 3138-3148.

Complete CAR data FCM

Fig.2 CD123-specific CARs can be expressed in healthy donor human T cells.

CAR Construction : 32716 scFv-28ζ Latest CAR Construction

Fig.2 CD123-specific CARs can be expressed in healthy donor human T cells.

Expression of indicated cell surface markers from 3 different healthy donor T-cell lines following immunomagnetic selection and 1 cycle of expansion. Data represent mean values ± standard error of the mean (SEM).

Mardiros, A., Dos Santos, C., McDonald, T., Brown, C. E., Wang, X., Budde, L. E., ... & Forman, S. J. (2013). T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia. Blood, The Journal of the American Society of Hematology, 122(18), 3138-3148.

Complete CAR data Cyt

Fig.3 Specific cytotoxicity of CD123-CAR–expressing T cells (26292 and 32716) against 293T cells expressing either CD123 (293T-CD123) or CD19 (293T-CD19) by chromium release assay.

CAR Construction : 32716 scFv-28ζ Latest CAR Construction

Fig.3 Specific cytotoxicity of CD123-CAR–expressing T cells (26292 and 32716) against 293T cells expressing either CD123 (293T-CD123) or CD19 (293T-CD19) by chromium release assay.

Data represent mean values of triplicate wells ± standard deviation (SD).

Mardiros, A., Dos Santos, C., McDonald, T., Brown, C. E., Wang, X., Budde, L. E., ... & Forman, S. J. (2013). T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia. Blood, The Journal of the American Society of Hematology, 122(18), 3138-3148.

Complete CAR data Cyt

Fig.4 Specific cytotoxicity of CD123-CAR T cells (26292 and 32716) against the CD19+CD123+ LCL cell line and the CD19-CD123+ cell line KG1a by chromium release assay.

CAR Construction : 32716 scFv-28ζ Latest CAR Construction

Fig.4 Specific cytotoxicity of CD123-CAR T cells (26292 and 32716) against the CD19+CD123+ LCL cell line and the CD19-CD123+ cell line KG1a by chromium release assay.

OKT3-expressing LCL (LCL-OKT3) and the CD19- CD123- K562 cell lines were used as positive and negative control cell lines, respectively. Data represent mean values of triplicate wells ± SD.

Mardiros, A., Dos Santos, C., McDonald, T., Brown, C. E., Wang, X., Budde, L. E., ... & Forman, S. J. (2013). T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia. Blood, The Journal of the American Society of Hematology, 122(18), 3138-3148.

Complete CAR data FuncS

Fig.5 Cytokine release analysis of CD123-specific CAR-expressing T cells coculture with CD123-expressing tumor cell lines.

CAR Construction : 32716 scFv-28ζ Latest CAR Construction

Fig.5 Cytokine release analysis of CD123-specific CAR-expressing T cells coculture with CD123-expressing tumor cell lines.

CD123 CAR T cells, or control pair-matched T cells, from 3 healthy donors were cocultured with the indicated cell lines for 24 hours at an E:T of 10:1 and the release of IFN-γ and TNF-α were quantified by Luminex multiplex bead technology. Fold elevation of IFN-γ production against KG1a compared with K562 for 26292 and 32716 were 2.3 and 19.1, respectively. Fold elevation of TNF-α production against KG1a compared with K562 for 26292 and 32716 was 5.5 and 16.5, respectively.

Mardiros, A., Dos Santos, C., McDonald, T., Brown, C. E., Wang, X., Budde, L. E., ... & Forman, S. J. (2013). T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia. Blood, The Journal of the American Society of Hematology, 122(18), 3138-3148.

Complete CAR data FuncS

Fig.6 Activation of multiple CD4 and CD8 effector functions by CD123-specific CARs following coculture with primary AML samples.

CAR Construction : 32716 scFv-28ζ Latest CAR Construction

Fig.6 Activation of multiple CD4 and CD8 effector functions by CD123-specific CARs following coculture with primary AML samples.

CAR-engineered T cells were cocultured for 6 hours with 3 different primary AML patient samples and analyzed for surface CD107a expression and intracellular IFN-γ or TNF-α production. (A, bar graphs) Percentage of DAPI-CD3+CD8+ EGFRt+ cells expressing CD107a. Data represent mean values + SD. (A, pie charts) The fractions of CD3+CD8+EGFRt+ cells undergoing degranulation and producing IFN-γ and/or TNF-α are plotted in the pie charts. Percentages in each subset are indicated. (B)

Mardiros, A., Dos Santos, C., McDonald, T., Brown, C. E., Wang, X., Budde, L. E., ... & Forman, S. J. (2013). T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia. Blood, The Journal of the American Society of Hematology, 122(18), 3138-3148.

Complete CAR data FuncS

Fig.7 Primary AML cells are specifically targeted by CD123 specific T cells.

CAR Construction : 32716 scFv-28ζ Latest CAR Construction

Fig.7 Primary AML cells are specifically targeted by CD123 specific T cells.

CD123-specific T cells were cocultured for 4 hours with 51Cr labeled CD34+ primary AML samples at an E:T of 25:1. Pre-B ALL 802 is a primary patient sample double positive for CD19 and CD123.

Mardiros, A., Dos Santos, C., McDonald, T., Brown, C. E., Wang, X., Budde, L. E., ... & Forman, S. J. (2013). T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia. Blood, The Journal of the American Society of Hematology, 122(18), 3138-3148.

Complete CAR data FuncS

Fig.8 CD123 CAR T cells exhibit antileukemic effects in vivo.

CAR Construction : 32716 scFv-28ζ Latest CAR Construction

Fig.8 CD123 CAR T cells exhibit antileukemic effects in vivo.

Bioluminescent imaging prior to T-cell treatment (day 4), on day 12, and on day 33 following KG1a-GFP-firefly luciferase transplantation.

Mardiros, A., Dos Santos, C., McDonald, T., Brown, C. E., Wang, X., Budde, L. E., ... & Forman, S. J. (2013). T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia. Blood, The Journal of the American Society of Hematology, 122(18), 3138-3148.

Complete CAR data FuncS

Fig.9 CD123 CAR T cells exhibit antileukemic effects in vivo.

CAR Construction : 32716 scFv-28ζ Latest CAR Construction

Fig.9 CD123 CAR T cells exhibit antileukemic effects in vivo.

Bioluminescent signal for each treatment group over time. Dotted line represents day of T-cell treatment. Data represent mean values of each group +/- SD. Results represent pooled data from 2 separate experiments. PBS n=3; CD19R, 26292, 32716 n=6.

Mardiros, A., Dos Santos, C., McDonald, T., Brown, C. E., Wang, X., Budde, L. E., ... & Forman, S. J. (2013). T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia. Blood, The Journal of the American Society of Hematology, 122(18), 3138-3148.

Complete CAR data FuncS

Fig.10 CD123 CAR T cells exhibit antileukemic effects in vivo.

CAR Construction : 32716 scFv-28ζ Latest CAR Construction

Fig.10 CD123 CAR T cells exhibit antileukemic effects in vivo.

Summary of leukemic cell engraftment in mouse peripheral blood 32 days after leukemia transplant. The percentage of viable human CD45+GFP+ KG1a cells is indicated. Each symbol indicates 1 mouse; bars represent mean values, and mean values for each group are indicated.

Mardiros, A., Dos Santos, C., McDonald, T., Brown, C. E., Wang, X., Budde, L. E., ... & Forman, S. J. (2013). T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia. Blood, The Journal of the American Society of Hematology, 122(18), 3138-3148.

Complete CAR data FuncS

Fig.11 CD123 CAR T cells exhibit antileukemic effects in vivo.

CAR Construction : 32716 scFv-28ζ Latest CAR Construction

Fig.11 CD123 CAR T cells exhibit antileukemic effects in vivo.

Kaplan-Meier analysis of survival for each group (PBS n 5 3, CD19R n=4, CD123-specific n=10). Log-rank (Mantel-Cox) tests were used to perform statistical analyses of survival between groups. *P <0.05.

Mardiros, A., Dos Santos, C., McDonald, T., Brown, C. E., Wang, X., Budde, L. E., ... & Forman, S. J. (2013). T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia. Blood, The Journal of the American Society of Hematology, 122(18), 3138-3148.

More Published Data More Published Data

Customer Reviews and Q&As

There are currently no customer reviews or questions for Anti-CD123 (32716) h(CD28-41BB-CD3ζ) CAR, pCDCAR1 (CAR-YF406). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.